Ocugen Inc (OCGN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Ocugen Inc stock (OCGN) is currently trading at $1.95. Ocugen Inc PS ratio (Price-to-Sales) is 156.04. Analyst consensus price target for OCGN is $10.60. WallStSmart rates OCGN as Sell.
- OCGN PE ratio analysis and historical PE chart
- OCGN PS ratio (Price-to-Sales) history and trend
- OCGN intrinsic value — DCF, Graham Number, EPV models
- OCGN stock price prediction 2025 2026 2027 2028 2029 2030
- OCGN fair value vs current price
- OCGN insider transactions and insider buying
- Is OCGN undervalued or overvalued?
- Ocugen Inc financial analysis — revenue, earnings, cash flow
- OCGN Piotroski F-Score and Altman Z-Score
- OCGN analyst price target and Smart Rating
Ocugen Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Ocugen Inc (OCGN) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, revenue growth. Concerns around return on equity and price/sales. Significant fundamental concerns warrant caution or avoidance.
Ocugen Inc (OCGN) Key Strengths (2)
Keeps $8559 of every $100 in revenue after operating costs
Revenue surging 54.20% year-over-year
Supporting Valuation Data
Ocugen Inc (OCGN) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 156.0x annual revenue
Very expensive at 149.2x book value
Low institutional interest, mostly retail-driven
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Ocugen Inc (OCGN) Detailed Analysis Report
Overall Assessment
This company scores 32/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 2.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Revenue Growth. Profitability is solid with Operating Margin at 8559.00%. Growth metrics are encouraging with Revenue Growth at 54.20%.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Price/Book. Some valuation metrics including Price/Sales (156.04), Price/Book (149.16) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -777.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -777.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 54.20% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
OCGN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
OCGN's Price-to-Sales ratio of 156.04x sits near its historical average of 142.87x (43th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 15% below its historical high of 184.27x set in Mar 2026, and 59% above its historical low of 98.14x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~110.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Ocugen Inc (OCGN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Ocugen Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 4M with 54% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 54% YoY, reaching 4M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 242% of revenue (11M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -14M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Ocugen Inc maintain 54%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.90, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Ocugen Inc.
Bottom Line
Ocugen Inc is a high-conviction growth story with revenue accelerating at 54% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Ocugen Inc(OCGN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.